LAVA Therapeutics' ( LVTX - Free Report ) shares were up almost 27% on Jun 1, after market hours. This followed soon after Janssen Biotech, a subsidiary of Johnson & Johnson ( JNJ - Free Report ), announced that it selected a lead candidate for further development in clinical studies for cancer.